The FDA is aware of the potential opportunities that cannabis or cannabis-derived compounds, such as cannabidiol (CBD), can offer. However, the agency is committed to protecting public health and taking steps to improve the efficiency of regulatory pathways for the legal marketing of cannabis and appropriate cannabis-derived products.